Do not miss AIBILI’s speakers at the roundtables on Personalised Medicine (Inês Pereira Marques) and Big Data/Artificial Intelligence (Luis Mendes).
This Friday, September 16th during the Technology Exhibition dedicated to Health Innovation organised by the Coimbra University and AIBILI.
More information here: https://www.uc.pt/ucbusiness/inovacao-em-saude/
AIBILI has been recognized as a Technology and Innovation Center.
The Technology and Innovation Centers (CTI) are entities dedicated to the production, dissemination and transmission of knowledge, oriented to companies and the creation of economic value, contributing, to the pursuit of public policy objectives, framed in the areas of national priority expertise or regions in which they operate.
ANI was responsible for this process that falls under the Recovery and Resilience Program (PRR).
More information: https://files.dre.pt/2s/2022/08/152000002/0000200003.pdf
The Honorary President of AIBILI, Prof. José Cunha-Vaz, was distinguished today, June 9th, in Berlin, Germany, with the Arnall Patz Medal. The Arnall Patz Medal is intended to distinguish outstanding contributions to the study of Retinal Vascular Diseases. The ceremony took place during the 45th Congress of the Macula Society.
This distinction is recognition of the scientific career and clinical research activity of José Cunha-Vaz, evident in his innovative contributions, which over the years have greatly contributed to the knowledge and treatment of retinal diseases, and more particularly diabetic retinopathy, a leading cause of blindness.
AIBILI is happy to participate in the Azores Health Summit which will take place on 12-13/05/2022. Our President, Prof. Conceição Lobo, will share AIBILI’s experience in the development and implementation of diabetic retinopathy screening programmes using artificial intelligence. This participation will be complemented by João Diogo Ramos from our partnering company Retmarker SA.
We are honoured to see our recent US Patent published representing another major milestone in AIBILI’s history. This patent US 11,2354,591 B2 follows the EU Patent EP3289565A1 that was received in August 2020.
The team lead by the inventors José Cunha-Vaz and Torcato Santos have developed a method and device that detects and quantifies abnormal increases of retinal extra cellular space using sites of low optical reflectivity from optical coherence tomography (OCT).
This non-invasive method detects changes in the blood-retinal barrier enabling timely treatment and therapy validation in the early stages of diabetic retinopathy.
Do not miss the opportunity to hear about AIBILI Data Centre and its relevance for clinical research development.
Carlos Domingues, AIBILI DataCentre Director will participate in this conference taking place on May 19, 2022, in Porto, Portugal.
This AIBILI infrastructure is the unique DataCentre in the Peninsula Iberia certified by ECRIN.
AIBILI has participated through his Projects and Tech Transfer Manager, Daniel Sanches Fernandes, in the EATRIS PORTUGAL Hub Meeting on April 27, 2022 at INFARMED, I.P. in Lisbon.
The AIBILI 2021 report is now available. Please download it here.
Congratulations to our Investigators Cláudia Farinha and Patrícia Barreto that were awarded with the Prémio Plácido during the 64th Congress of the Portuguese Ophthalmology Society with the paper GENETIC CHARACTERIZATION OF AMD IN THE COIMBRA EYE STUDY – Common and Rare Risk Variants & Genetic Risk Score (GRS) .
This is the first genetic study in AMD in a Portuguese population. According to our results, several variants were found to be associated with the presence and progression to AMD in our cohort, while others were protective. Furthermore, damaging rare variants in the CFH gene were cumulatively more common in AMD patients and the GRS was significantly different between AMD and non-AMD individuals. Our study adds new information regarding the genetics of AMD in a European population, which can be used for comparison with other populational cohorts and further expand the knowledge of AMD pathophysiology.
During the 8th Forum on Management of Research Data that will take place in Coimbra, Portugal, on November 25-26, 2021, AIBILI will be presenting two talks by Carlos Domingues and Pier Basile. Program available here (Programa | Fórum de Gestão de Dados de Investigação (rcaap.pt))
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas medidas para minimizar o risco de eventos adversos cardiovasculares major na utilização de Tofacitinib (Xeljanz▼), do risco de reações adversas cutâneas graves (SCARs) com atezolizumab (Tecentriq▼) e outros medicamentos anticancerígenos imunoestimuladores e também dos relatos de doença pulmonar intersticial e pneumonite com inibidores da CDK4/6. Destaca-se ainda informação sobre as vacinas aprovadas e em avaliação para a prevenção da COVID-19, assim como os tratamentos em avaliação e aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no segundo e terceiro trimestres de 2021.
Consulte: Farmacovigilancia – Atualizacoes de segurança de Medicamentos Vol8 N2 e 3
Our honorary president, Prof. José Cunha-Vaz has spoken to the newspaper “Campeão das Provincias” in the scope of the #worldSightDay, celebrated today, October 14!
In this communication, Prof. Cunha-Vaz raises the awareness for the current need on visual health, not only for diseases related to aging as diabetic retinopathy, glaucoma or AMD, but particularly for the current eye care required due to visual problems caused by the excessive use of technologic devices.
We are happy to announce that AIBILI is part of the PTCentroDiH – a regional hub to support small and medium-sized enterprises addressing the digital transformation challenge ahead.
PTCentroDiH aims to act as a one-stop-shop to foster competitiveness, innovation and territorial cohesion in the Centro Region of Portugal. Among 21 entities AIBILI will specifically contribute with cybersecurity and artificial intelligence services.
AIBILI has a Data Centre certified by ECRIN (unique in the Iberian Peninsula certified by this standard) that gives PTCentroDiH a strategic position in clinical research, and data management in accordance with the regulations.
AIBILI has also extensive experience in algorithms’ development, which that allows the automatic detection of injuries/ anomalous conditions in ophthalmic images, as well as in the development of projects within the scope of artificial intelligence.
For more information please visit www.ptcentrodih.pt
A AIBILI através do Dr. João Pedro Marques, grader e coordenador médico do CORC, contribui para o estudo inovador PIONEER, publicado na Nature (artigo) no qual foi demonstrada uma terapia revolucionária para recuperação parcial de visão em doentes com retinitis pigmentosa.
Este trabalho foi ontem destacado no Jornal da Tarde da RTP. A reportagem pode ser vista neste link
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca do risco aumentado de hemorragia pós-parto associada à utilização de medicamentos antidepressivos das classes SSRI e SNRI, do risco de lesão hepática severa e meningoencefalite herpética associada ao fingolimod, do risco de leucoencefalopatia multifocal progressiva e linfopenia ligeira associado ao dimetil fumarato e sobre o risco de insuficiência adrenal aguda em crianças após alteração de forma farmacêutica da hidrocortisona. Destaca-se ainda a informação sobre as vacinas aprovadas e em avaliação para a COVID-19, assim como dos tratamentos em avaliação e aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no primeiro trimestre de 2021.
Consulte: Farmacovigilancia – Atualizações de segurança de Medicamentos Vol.8 Nº1
ONLINE COURSE
Optical Coherence Tomography in the Posterior Segment – OCT and OCT-angiography
April 17, 2021, 8:30 – 13h [GMT]
Registration free but mandatory here: https://bit.ly/3sbzkOK
Last March 18, the European Medicines Agency (EMA) announced the selected consortium to monitor possible adverse events to COVID-19 vaccines in Europe for the next 3 years.
The consortium, led by the Netherlands, includes 13 countries and the Portuguese participation is coordinated by UFC, leaded by Prof. Francisco Batel Marques. Entitled “Monitoring the safety of covid-19 vaccines in the EU”, the study has the contribution of Portugal, through a collaboration agreement between the pharmacovigilance units of Coimbra (AIBILI-UFC and Faculty of Pharmacy of UC), Porto (Faculty of Medicine) and Lisbon (Faculty of Pharmacy).
“It is very important, from the point of view of public health, to have reliable information on the safety of vaccines”, said Prof. Francisco Batel Marques, observing also that the time of research and development was relatively short.
The project is now in preparation to start in agreement with all details approved by EMA.
More information: https://expresso.pt/coronavirus/2021-03-22-Covid-19.-Portugal-integra-projeto-europeu-para-fiscalizar-seguranca-das-vacinas-1c594763
We have receive our renewal of Data Centre (DC) certification by ECRIN – European Clinical Research Infrastructure Network!
This is an important mark for AIBILI as it stands that our DC meets the ECRIN requirements for IT and Data Management within Clinical Trials, as per the conclusions of an independent risk based audit.
Moreover, we were the first European DC to obtain a certification renewal!
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca dos casos de hipertensão grave e síndrome de encefalopatia posterior reversível associada à utilização de niparaib, do risco de hipofosfatemia sintomática associada à carboximaltose férrica, do risco aumentado de malformações congénitas quando o modafinil é utilizada na gravidez e sobre precauções a ter no tratamento com eritromicina. Destaca-se ainda a informação de segurança sobre vacinas aprovadas para a COVID-19 e informa-se dos tratamentos aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no quarto trimestre de 2020.
Consulte: Farmacovigilancia-Atualizacoes-de-seguranca-de-medicamentos-Vol7-N4
AIBILI and Pathway Health Consulting are organizing a session focused on Funding and Prices of medicines in Portugal
The session will opened by Prof. Francisco Batel-Marques and count with a presentation by Cláudia Furtado (Head of the Health Technology Assessment, Pricing and Reimbursement, INFARMED, I.P.) followed by Q&A.
Registration here: http://z08er.qr.ai
